AEGB.F Stock Overview
A diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
AegirBio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.11 |
| 52 Week High | kr0.19 |
| 52 Week Low | kr0.11 |
| Beta | 2.58 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| AEGB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 1.6% |
| 1Y | n/a | 7.0% | 26.1% |
Return vs Industry: Insufficient data to determine how AEGB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AEGB.F performed against the US Market.
Price Volatility
| AEGB.F volatility | |
|---|---|
| AEGB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AEGB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AEGB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 15 | Marco Wititteveen | aegirbio.com |
AegirBio AB (publ), a diagnostic company, develops and commercializes tests for monitoring and optimizing the dosage of biological drugs Sweden and internationally. The company focuses on the neurology, oncology, and autoimmune therapeutic areas. It offers moNATor, a first dose-monitoring laboratory test that provides multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit.
AegirBio AB (publ) Fundamentals Summary
| AEGB.F fundamental statistics | |
|---|---|
| Market cap | US$2.18m |
| Earnings (TTM) | -US$35.17m |
| Revenue (TTM) | US$9.49k |
229.4x
P/S Ratio-0.1x
P/E RatioIs AEGB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AEGB.F income statement (TTM) | |
|---|---|
| Revenue | kr99.00k |
| Cost of Revenue | kr24.25m |
| Gross Profit | -kr24.15m |
| Other Expenses | kr342.85m |
| Earnings | -kr367.00m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.89 |
| Gross Margin | -24,398.99% |
| Net Profit Margin | -370,709.09% |
| Debt/Equity Ratio | 455.0% |
How did AEGB.F perform over the long term?
See historical performance and comparison